Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bitopertin - Disc Medicine

Drug Profile

Bitopertin - Disc Medicine

Alternative Names: DISC-1459; Heme synthesis modulator - Disc Medicine; R-1678; RG 6718; RG-6178; RG1678; RO-4917838

Latest Information Update: 26 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Chugai Pharmaceutical; Disc Medicine; Roche
  • Class Antianaemics; Antipsychotics; Behavioural disorder therapies; Piperazines; Pyridines; Skin disorder therapies; Small molecules
  • Mechanism of Action Glycine transporter 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Erythropoietic protoporphyria
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Erythropoietic protoporphyria
  • Phase I/II Diamond-Blackfan syndrome
  • Preclinical Myelodysplastic syndromes
  • Discontinued Beta-thalassaemia; Obsessive-compulsive disorders; Schizophrenia

Most Recent Events

  • 21 Mar 2024 Disc Medicine completed enrollment of phase II programme of bitopertin in erythropoietic porphyrias
  • 13 Dec 2023 Updated safety and efficacy data from a phase II BEACON trial in Erythropoietic protoporphyria released by (Company)
  • 09 Dec 2023 Pharmacodynamics data from a preclinical studies in Diamond-Blackfan syndrome presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top